Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14695733 | 0.92 | GABRA1 (0.53) | GABRA1GABRB2CNR2CNR1ALOX5 | |
| SCHEMBL10433454 | 0.86 | KDM4E (0.56) | GABRA1GABRB2KDM4EALDH1A1ELANE | |
| SCHEMBL8072797 | 0.84 | KDM4E (0.60) | CNR2CNR1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3461924 | 0.83 | CNR2 (0.48) | CNR2CNR1ALOX5KDM4EALDH1A1 | |
| SCHEMBL2848296 | 0.82 | GABRA1 (0.49) | GABRA1GABRB2KDM4EALDH1A1ELANE | |
| SCHEMBL28783874 | 0.81 | KDM4E (0.60) | CNR2CNR1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3460898 | 0.81 | CNR2 (0.46) | GABRA1GABRB2CNR2CNR1ALOX5 | |
| SCHEMBL4960145 | 0.80 | CYP1A2 (0.57) | ALOX5PTGS2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28158323 | 0.80 | KDM4E (0.58) | CNR2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL6061598 | 0.80 | ALOX5 (0.55) | GABRA1GABRB2CNR2CNR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | OCERA THERAPEUTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20100190865-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, Lymanria dispar | SIMON FRASER UNIVERSITY (CA) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | GHSR, GHRHR, GIPR | GABRA1 340/4885GABRB2 371/4885CNR2 228/4885 |
| US-20100190865-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, Lymanria dispar | L3MBTL3, L3MBTL4, L3MBTL1 | GABRA1 618/4885GABRB2 473/4885CNR2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.